RankingsPricing
  1. US-listed companies
  2. REGENERON PHARMACEUTICALS, INC.
  3. Financials
  4. Total cash & short-term investments

REGENERON PHARMACEUTICALS, INC.REGN

Market cap
$82.2B
P/E ratio
SummaryFinancials
Period EndTotal cash & short-term investments (Million USD)YoY (%)
Dec 31, 20249,013-16.95%
Dec 31, 202310,853+39.93%
Dec 31, 20227,756+35.90%
Dec 31, 20215,707+58.51%
Dec 31, 20203,601+11.58%
Dec 31, 20193,227+14.33%
Dec 31, 20182,822+100.24%
Dec 31, 20171,410+35.70%
Dec 31, 20161,039-0.63%
Dec 31, 20151,045+16.07%
Dec 31, 2014900+29.76%
Dec 31, 2013694+125.25%
Dec 31, 2012308-41.53%
Dec 31, 2011527+111.31%
Dec 31, 2010249

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)